{"id":"cladribine-clad","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"71c39b37-33b5-42e1-bf4f-93ff751cc7fe","title":"CLADRIBINE INJECTION, SOLUTION [HISUN PHARMACEUTICALS USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cladribine is a deoxyadenosine analog that accumulates preferentially in lymphocytes due to high deoxycytidine kinase activity and low 5'-nucleotidase activity in these cells. Once phosphorylated, it is incorporated into DNA where it causes strand breaks and triggers apoptosis, leading to selective depletion of T and B lymphocytes. This mechanism makes it effective in hematologic malignancies and autoimmune conditions.","oneSentence":"Cladribine is a purine nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, causing strand breaks and apoptosis in lymphoid cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:15.573Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hairy cell leukemia"},{"name":"Chronic lymphocytic leukemia"},{"name":"Multiple sclerosis (relapsing-remitting)"}]},"trialDetails":[{"nctId":"NCT06232655","phase":"PHASE2","title":"Cladribine Venetoclax in Monocytic AML","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07032727","phase":"PHASE2","title":"Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-12","conditions":"Targeted Therapy, IDH1-Mutated Malignancies, Mutations","enrollment":68},{"nctId":"NCT04934800","phase":"","title":"Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2019-12-10","conditions":"Multiple Sclerosis","enrollment":256},{"nctId":"NCT06561152","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-02-10","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04640818","phase":"","title":"Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy","status":"UNKNOWN","sponsor":"Claudio Gobbi","startDate":"2020-12-17","conditions":"Multiple Sclerosis","enrollment":45},{"nctId":"NCT03602131","phase":"PHASE2","title":"Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2019-01-01","conditions":"Hodgkin Lymphoma, Non-hodgkin Lymphoma","enrollment":30},{"nctId":"NCT03151876","phase":"PHASE2","title":"Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2017-06-12","conditions":"Lymphoma","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cladribine (CLAD)","genericName":"Cladribine (CLAD)","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cladribine is a purine nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, causing strand breaks and apoptosis in lymphoid cells. Used for Hairy cell leukemia, Chronic lymphocytic leukemia, Multiple sclerosis (relapsing-remitting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}